Wall Street Zen upgraded shares of AxoGen (NASDAQ:AXGN – Free Report) from a buy rating to a strong-buy rating in a research note published on Monday morning,Wall Street Zen reports.
Several other analysts have also issued reports on AXGN. Truist Financial upped their price target on shares of AxoGen from $53.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Bank of America started coverage on AxoGen in a report on Monday, October 12th. They issued a “buy” rating and a $52.00 price objective on the stock. HC Wainwright lifted their price objective on AxoGen from $53.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Canaccord Genuity Group boosted their target price on AxoGen from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Finally, Raymond James Financial restated an “outperform” rating and set a $57.00 target price on shares of AxoGen in a report on Thursday, October 29th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.92.
Read Our Latest Analysis on AXGN
AxoGen Stock Down 1.0%
Shares of AXGN opened at $55.38 on Monday. The firm has a market cap of $3.31 billion, a P/E ratio of -85.20 and a beta of 1.21. The stock has a 50 day simple moving average of $43.41 and a two-hundred day simple moving average of $40.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 12.02 and a quick ratio of 10.67. AxoGen has a 1 year low of $23.00 and a 1 year high of $59.72.
AxoGen (NASDAQ:AXGN – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $73.45 million. AxoGen had a negative net margin of 11.96% and a negative return on equity of 5.35%. On average, analysts forecast that AxoGen will post -0.36 earnings per share for the current fiscal year.
Insider Transactions at AxoGen
In other AxoGen news, Director Joseph Tyndall sold 3,500 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the completion of the sale, the director owned 10,650 shares in the company, valued at approximately $529,305. This trade represents a 24.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.44% of the stock is currently owned by corporate insiders.
Institutional Trading of AxoGen
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXGN. Nykredit A S purchased a new position in AxoGen during the 2nd quarter valued at $30,000. Global Retirement Partners LLC raised its holdings in AxoGen by 2,822.7% in the 3rd quarter. Global Retirement Partners LLC now owns 643 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 621 shares in the last quarter. KBC Group NV purchased a new stake in shares of AxoGen in the 1st quarter worth about $41,000. Sterling Capital Management LLC lifted its position in shares of AxoGen by 858.9% in the 3rd quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 1,589 shares during the period. Finally, State of Alaska Department of Revenue lifted its position in shares of AxoGen by 16.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock worth $118,000 after purchasing an additional 409 shares during the period. Hedge funds and other institutional investors own 80.29% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company’s offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.
Further Reading
- Five stocks we like better than AxoGen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
